28072 Federal Register / Vol. 72, No.
96 / Friday, May 18, 2007 / Notices
Cambrex Charles City, Inc. to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Cambrex Charles City, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9609 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 25, 2006, and
published in the Federal Register on
November 1, 2006, (71 FR 64298),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
pwalker on PROD1PC71 with NOTICES
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
VerDate Aug<31>2005 17:06 May 17, 2007 Jkt 211001
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9625 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 16, 2007, and
published in the Federal Register on
January 23, 2007, (72 FR 2907),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Remifentanil (9739) ......................
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
PO 00000 Frm 00054 Fmt 4703 Sfmt 4703
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9642 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 21, 2006,
and published in the Federal Register
on December 1, 2006, (71 FR 69589–
69590), Chattem Chemicals, Inc., 3801
St. Elmo Avenue, Building 18,
Chattanooga, Tennessee 37409, made
application by renewal and by letter to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug Schedule
4–Methoxyamphetamine (7411) ... I
Dihydromorphine (9145) ............... I
Schedule Difenoxin (9168) ........................... I
Amphetamine (1100) .................... II
I Methamphetamine (1105) ............ II
I Methylphenidate (1724) ................ II
II Pentobarbital (2270) ..................... II
II
Codeine (9050) ............................. II
II Dihydrocodeine (9120) ................. II
II Oxycodone (9143) ........................ II
II Hydromorphone (9150) ................ II
II Hydrocodone (9193) ..................... II
II Meperidine (9230) ........................ II
Dextropropoxyphene, bulk (non- II
dosage forms) (9273).
Morphine (9300) ........................... II
Thebaine (9333) ........................... II
Oxymorphone (9652) ................... II
Noroxymorphone (9668) .............. II
Alfentanil (9737) ........................... II
Sufentanil (9740) .......................... II
Fentanyl (9801) ............................ II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
By letter dated February 15, 2007,
Chattem Chemicals has withdrawn their
request for N-Ethylamphetamine (1475),
Secobarbital (2315), 2,5–
Dimethoxyamphetamine (7396),
Diphenoxylate (9170), Opium Extracts
(9610), Opium Fluid Extract (9620),
Opium Tincture (9630), Opium
Powdered (9639), and Opium
Granulated (9640).
One comment has been received; this
comment has been noted and
considered by DEA.
E:\FR\FM\18MYN1.SGM 18MYN1